OS Therapies (OSTX) Cash from Operations (2023 - 2026)
OS Therapies' (OSTX) quarterly Cash from Operations came in at 4600000.0 in Q1 2026, down 33.65% YoY from 6932694.74 in Q1 2025, and down 24.6% on a QoQ basis from 3691670.0 in Q4 2025.
OS Therapies (OSTX) Cash from Operations (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Cash from Operations data on file, last reported at 4600000.0 in Q1 2026.
- Quarterly Cash from Operations fell 33.65% year-over-year to 4600000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15358116.0 (down 52.33% YoY) and the FY2025 annual result came in at 14200000.0, down 94.99% from the prior year.
- Cash from Operations retreated to 4600000.0 in Q1 2026, from 3691670.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 428186.0 in Q1 2023 to a low of 4706192.0 in Q3 2025.
- A 4-year average of 2237635.54 and a median of 2360254.0 in 2025 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations fell 6.03% — and 2025, when it sank 436.35%.
- Tracing OSTX's Cash from Operations over 4 years: stood at 871160.0 in 2023, then sank by 172.58% to 2374577.0 in 2024, then tumbled by 55.47% to 3691670.0 in 2025, then retreated by 24.6% to 4600000.0 in 2026.
- The last three Cash from Operations figures came in at 4600000.0 (Q1 2026), 3691670.0 (Q4 2025), and 4706192.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | OS Therapies | 19.31 Mn | 19.31 Mn | - | -5.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.60 Mn |
| Mar 31, 2026 | -4.60 Mn |
| Dec 31, 2025 | -3.69 Mn |
| Dec 31, 2025 | -3.69 Mn |
| Sep 30, 2025 | -4.71 Mn |
| Sep 30, 2025 | -4.71 Mn |
| Jun 30, 2025 | -2.36 Mn |
| Jun 30, 2025 | -2.36 Mn |
| Mar 31, 2025 | -3.44 Mn |
| Mar 31, 2025 | -3.44 Mn |
| Dec 31, 2024 | -2.37 Mn |
| Dec 31, 2024 | -2.37 Mn |
| Sep 30, 2024 | -3.38 Mn |
| Sep 30, 2024 | -3.38 Mn |
| Jun 30, 2024 | -881,191.00 |
| Jun 30, 2024 | -881,191.00 |
| Mar 31, 2024 | -641,729.00 |
| Mar 31, 2024 | -641,729.00 |
| Dec 31, 2023 | -871,160.00 |
| Dec 31, 2023 | -871,160.00 |